🎉 M&A multiples are live!
Check it out!

Galectin Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Galectin Therapeutics and similar public comparables like Vivoryon Therapeutics, Pharming, and Benevolent AI.

Galectin Therapeutics Overview

About Galectin Therapeutics

Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.


Founded

2001

HQ

United States of America
Employees

15

Financials

LTM Revenue n/a

LTM EBITDA n/a

EV

$178M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Galectin Therapeutics Financials

Galectin Therapeutics has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Galectin Therapeutics achieved revenue of n/a and an EBITDA of -$41.5M.

Galectin Therapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Galectin Therapeutics valuation multiples based on analyst estimates

Galectin Therapeutics P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a n/a XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$38.2M -$41.5M XXX XXX XXX
EBITDA Margin -Infinity% -Infinity% XXX XXX XXX
Net Profit -$38.8M -$41.1M XXX XXX XXX
Net Margin -Infinity% -Infinity% XXX XXX XXX
Net Debt $21.2M $46.1M XXX XXX XXX

Financial data powered by Morningstar, Inc.

Galectin Therapeutics Stock Performance

As of April 15, 2025, Galectin Therapeutics's stock price is $1.

Galectin Therapeutics has current market cap of $84.7M, and EV of $178M.

See Galectin Therapeutics trading valuation data

Galectin Therapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$178M $84.7M XXX XXX XXX XXX $-0.80

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Galectin Therapeutics Valuation Multiples

As of April 15, 2025, Galectin Therapeutics has market cap of $84.7M and EV of $178M.

Galectin Therapeutics's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Galectin Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Galectin Therapeutics and 10K+ public comps

Galectin Therapeutics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $178M XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA -4.3x XXX XXX XXX
P/E -1.8x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -4.3x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Galectin Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Galectin Therapeutics Valuation Multiples

Galectin Therapeutics's NTM/LTM revenue growth is n/a

Galectin Therapeutics's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $2.8M for the same period.

Over next 12 months, Galectin Therapeutics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Galectin Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Galectin Therapeutics and other 10K+ public comps

Galectin Therapeutics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth n/a XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth 8% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee $2.8M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue n/a XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Galectin Therapeutics Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Galectin Therapeutics M&A and Investment Activity

Galectin Therapeutics acquired  XXX companies to date.

Last acquisition by Galectin Therapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . Galectin Therapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Galectin Therapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Galectin Therapeutics

When was Galectin Therapeutics founded? Galectin Therapeutics was founded in 2001.
Where is Galectin Therapeutics headquartered? Galectin Therapeutics is headquartered in United States of America.
How many employees does Galectin Therapeutics have? As of today, Galectin Therapeutics has 15 employees.
Who is the CEO of Galectin Therapeutics? Galectin Therapeutics's CEO is Mr. Joel Lewis.
Is Galectin Therapeutics publicy listed? Yes, Galectin Therapeutics is a public company listed on NAS.
What is the stock symbol of Galectin Therapeutics? Galectin Therapeutics trades under GALT ticker.
When did Galectin Therapeutics go public? Galectin Therapeutics went public in 2002.
Who are competitors of Galectin Therapeutics? Similar companies to Galectin Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Galectin Therapeutics? Galectin Therapeutics's current market cap is $84.7M
Is Galectin Therapeutics profitable? Yes, Galectin Therapeutics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.